Skip to main content
. 2022 Aug 19;54(11):1708–1719. doi: 10.3724/abbs.2022112

Figure 4 .


Figure 4

Knockdown of AHNAK2 inhibits tumor progression and metastasis of adenocarcinomas

(A–D) Kaplan-Meier analysis of the relationship between the expression of AHNAK2 and the overall survival prognosis of breast cancer patients (A), colorectal cancer patients (B), lung adenocarcinoma patients (C) and pancreatic cancer patients (D). (E,F) The tumor volume of each group was assessed post-transplantation. Images showed the dissected tumors after subcutaneous injection of Hela (E) and in situ injections of MDA-MB-231 (F). (G,H) Bioluminescence images of AHNAK2-deficient and the control nude mice collected after intracardial injection of Hela (G) and MDA-MB-231 (H) cells. (I,J) Representative lung metastasis areas and quantitative results of Hela cells (I) and MDA-MB-231 cells (J) after tail vein injection. * P<0.05, ** P<0.01, *** P<0.001.